Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 90.8% in May

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large decrease in short interest in May. As of May 15th, there was short interest totaling 75,959 shares, a decrease of 90.8% from the April 30th total of 821,485 shares. Based on an average daily trading volume, of 703,441 shares, the short-interest ratio is presently 0.1 days. Currently, 6.2% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aspire Biopharma in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ASBP. Jane Street Group LLC boosted its position in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Aspire Biopharma in the third quarter valued at approximately $28,000. Finally, XTX Topco Ltd increased its holdings in shares of Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after purchasing an additional 237,620 shares during the last quarter. 19.17% of the stock is owned by institutional investors and hedge funds.

Aspire Biopharma Trading Down 7.9%

Shares of NASDAQ:ASBP opened at $4.67 on Thursday. Aspire Biopharma has a twelve month low of $3.31 and a twelve month high of $1,050.36. The company’s 50 day moving average is $15.99 and its 200 day moving average is $63.48. The company has a market cap of $6.05 million, a PE ratio of -0.04 and a beta of 0.21.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($20.57) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million during the quarter.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.